The Groningen-based medtech and deeptech start-up Sencilia has raised approximately €2 million to further develop the Rely-V® sensor technology. The financing round consists of investments from Future Tech Ventures (FTV), NV NOM (Investment and Development Company for Northern Netherlands), imec.istart, RUG Ventures, Triade, and private investors. In addition, Sencilia receives a grant through the European Eureka Eurostars program and an innovation loan from Rabobank.
“This investment helps us further develop our prototype towards production, collect more clinical data, and collaborate with manufacturers of infusion pumps and infusion sets. The investment also gives us the opportunity to continue growing as a company. Groningen plays an important role in this: many team members started at Sencilia as students, interns, or through small projects,” says Amar Kamat, founder and CEO of Sencilia.
Especially when patients receive very small amounts of medication, it can be difficult to detect problems with an IV in a timely manner. Sencilia’s smart sensor technology is designed to help healthcare providers identify such problems earlier, without having to drastically change their working methods. Rely-V® is attached to the outside of a standard IV tube and measures the actual flow rate, down to 0.1 milliliters per hour, without coming into contact with the medication.
The technology is initially being developed for the care of babies and children. These are vulnerable patients who often receive very small amounts of medication. In the future, the technology can also be used for other applications within infusion care.
Foto: Casper Maas
